Weinman 1 and Winston Dunn 1 , (1)University of Kansas Medical Center, (2)Medstar Washington Hospital Center / Georgetown University Background: Nonalcoholic fatty liver disease (NAFLD) affects approximately 26% of the US population, of which 2% develop nonalcoholic steatohepatitis (NASH) with advanced fibrosis or cirrhosis
These IV therapies are not commercially manufactured drugs, are not intended for home use or resale, and are designed to support general health and wellness, not to diagnose, treat, cure, or prevent any disease
A highly functioning liver is better equipped to handle environmental toxicants, necessary medications, and the heavy metabolic byproducts generated by chronic illness, ultimately reducing the overall toxic burden on the patient's system
It's important to understand that glutathione works as part of the body's natural processes rather than as a quick fix